Long Term Dietary Restriction of Advanced Glycation End-Products (AGEs) in Older Adults with Type 2 Diabetes Is Feasible and Efficacious-Results from a Pilot RCT
Open Access
- 15 October 2020
- Vol. 12 (10), 3143
- https://doi.org/10.3390/nu12103143
Abstract
Introduction: High serum concentrations of advanced glycation end-products (AGEs) in older adults and diabetics are associated with an increased risk of cognitive impairment. The aim of this pilot study was to assess the feasibility of long-term adherence to a dietary intervention designed to decrease intake and exposure to circulating AGEs among older adults with type 2 diabetes. Methods: Herein, 75 participants were randomized to either a standard of care (SOC) control arm or to an intervention arm receiving instruction on reducing dietary AGEs intake. The primary outcome was a change in serum AGEs at the end of the intervention. Secondary and exploratory outcomes included adherence to diet and its association with circulating AGEs. Cognitive function and brain imaging were also assessed but were out of the scope of this article (ClinicalTrials.gov Identifier: NCT02739971). Results: The intervention resulted in a significant change over time in several serum AGEs compared to the SOC guidelines. Very high adherence (above 80%) to the AGE-lowering diet was associated with a greater reduction in serum AGEs levels. There were no significant differences between the two arms in any other metabolic markers. Conclusions: A long-term dietary intervention to reduce circulating AGEs is feasible in older adults with type 2 diabetes, especially in those who are highly adherent to the AGE-lowering diet.This publication has 30 references indexed in Scilit:
- Effect of diet-derived advanced glycation end products on inflammationNutrition Reviews, 2015
- Advanced glycation endproducts in food and their effects on healthFood and Chemical Toxicology, 2013
- Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the DietJournal of the American Dietetic Association, 2010
- Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1Journal of Clinical Endocrinology & Metabolism, 2009
- Advanced glycation end‐products (AGEs) and heart failure: Pathophysiology and clinical implicationsEuropean Journal of Heart Failure, 2007
- Understanding RAGE, the receptor for advanced glycation end productsJournal of Molecular Medicine, 2005
- Advanced Glycation End Products in Human Cancer Tissues: Detection of Nε‐(Carboxymethyl)lysine and ArgpyrimidineAnnals of the New York Academy of Sciences, 2005
- Advanced glycation endproducts—role in pathology of diabetic complicationsDiabetes Research and Clinical Practice, 2005
- Advanced glycoxidation end products in commonly consumed foodsJournal of the American Dietetic Association, 2004
- Advanced glycation: an important pathological event in diabetic and age related ocular diseaseBritish Journal of Ophthalmology, 2001